Novartis

Novartis to buy UK biotech Myricx Bio for up to $1.5B

Novartis announced on Monday it has agreed to acquire UK-based biotechnology firm Myricx Bio for up to $1.5 billion, adding a novel cancer drug platform to its oncology pipeline as competition intensifies in the antibody-drug conjugate space.